In a report released today, George Farmer from Scotiabank maintained a Hold rating on Kura Oncology (KURA – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $20.85.
According to TipRanks, Farmer is a 5-star analyst with an average return of 29.0% and a 70.31% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Argenx Se, and Legend Biotech.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $31.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $22.92 and a one-year low of $7.41. Currently, Kura Oncology has an average volume of 1.52M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kura Oncology (KURA) Company Description:
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Read More on KURA:
- Kura Oncology’s KOMET-007 Trial Shows Promising Results
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology reports preliminary ziftomenib combination data
- Kura Oncology to hold a virtual investor event
- Kura Oncology Announces Private Placement Details
